Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

T-47D Giredestrant + palbociclib combination TraCe-seq (NGS4327)

ABSTRACT: T-47D Giredestrant + palbociclib combination TraCe-seq (NGS4327)

PROVIDER: PRJNA1082726 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28197713.fastq.gz	Fastqsanger.gz
	SRR28197714.fastq.gz	Fastqsanger.gz
	SRR28197715.fastq.gz	Fastqsanger.gz
	SRR28197716.fastq.gz	Fastqsanger.gz
	SRR28197717.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

T-47D Giredestrant + palbociclib combination TraCe-seq (NGS4327)

Project description:Barcoded clones of T-47D cells were treated with either giredestrant, palbociclib, or their combination for different duration. Barcodes and transcriptional profiles was measured by scRNA-seq.

2025-01-15 | GSE260703 | GEO

RNAseq analysis of taxol and palbociclib combination in pancreatic cancer

Project description:RNAseq from pancreatic cancer cell lines treated with DMSO, taxol, palbociclib or the combination at short-term time-points.

2020-02-06 | GSE135215 | GEO

Transcriptome modulation by long duration giredestrant treatment and the effect of GPX4 CRISPR KO in MCF7 cells

Project description:In the giredestrant resistance/sensitization CRISPR Ko whole genome screen in MCF7 cells, ferroptosis regulator GPX4 comes out as top sensitization hits. We like to see how GPX4 KO changes gene expression profiles, and how giredestrant alone and the combination of GPX4 KO and giredestrant long duration treatment modulate the transcriptome

2024-08-07 | GSE260702 | GEO

RNA-seq of human breast cancer cell lines MCF7 and T74D naive and resistant to palbociclib treated with capivasertib, fulvestrant and combination

Project description:T47D and MCF7 cell lines were treated with long-term (continuous) palbociclib to induce 4 resistant cell-lines (T47D RB-, T47D CDK6H, MCF7 RB- and MCF7 PacqR). Each cell line (both parental and resistant) were then treated with DMSO (control), capivasertib monotherapy, fulvestrant monotherapy and capivasertib/fulvestrant combination. RNA data is available after each treatment and resistant cell lines additionally have RNA data available after continuous palbociclib treatment.

2023-08-14 | E-MTAB-13262 | biostudies-arrayexpress

Inhibition of CDK6 using Palbociclib in combination with Ruxolitinib markedly improves myelofibrosis in murine models

Project description:Myelofibrosis (MF) is a deadly blood neoplasia that presents the worst prognosis among myeloproliferative neoplasms (MPN). Expression of CDK6 is significantly elevated in MPN/MF hematopoietic progenitor cells. In this study, we investigated the efficacy of CDK4/6 inhibitor Palbociclib alone or in combination with Ruxolitinib in Jak2V617F and MPLW515L murine models of MF. Treatment of Palbociclib alone significantly reduced leukocytosis, splenomegaly and inhibited bone marrow fibrosis in Jak2V617F and MPLW515L mouse models of MF. Combined treatment of Palbociclib and Ruxolitinib resulted in normalization of peripheral blood leukocyte counts, marked reduction of spleen size and abrogation of bone marrow fibrosis in murine models of MF. Mechanistically, we show that Palbociclib treatment or depletion of CDK6 inhibits Aurora kinase, NF-κB and TGF-β signaling pathways in Jak2V617F mutant hematopoietic cells. Overall, our data suggest that Palbociclib in combination with Ruxolitinib may have therapeutic potential for treatment of MF.

2021-11-05 | GSE173814 | GEO

Human breast cancer biopsies of patients treated or not with the combination of palbociclib and fulvestrant

Project description:Metastatic HR+ HER2- breast cancer is an intractable disease that resists to the first-line treatment based on the combination of CDK4/6 inhibitor and hormone therapy (HT). To identify targets that further increase palbociclib-HT efficacy, we utilized biopsies from cancer patients who showed recurrence after treatment, HR+HER2- luminal cancer cells sensitive and resistant to the palbociclib-HT. Proteomic analysis of human samples revealed an upregulation of the oxidative stress-triggered proteasome subunit alpha7 (PSMA7) in metastatic relapses in different organs after patient's resistance to palbociclib-HT combination.

2025-05-07 | PXD053296 | Pride

RNAseq analysis of taxol and palbociclib combination in pancreatic cancer

Project description:RNAseq analysis of taxol and palbociclib combination in pancreatic cancer

| PRJNA557802 | ENA

ATACseq on giredestrant-resistant ER+ breast cancer cell lines

Project description:Characterization of molecular features associated with giredestrant resistance in HR+ breast cancer cell line models

2026-02-13 | GSE295128 | GEO

RNAseq on giredestrant-resistant ER+ breast cancer cell lines

Project description:Characterization of molecular features associated with giredestrant resistance in HR+ breast cancer cell line models

2026-02-13 | GSE295127 | GEO

TRACE-RICE_Genomic_data

Project description:TRACE-RICE_Genomic_data_rice_variety_authentication